Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LASZLO L MECHTLER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1710978598
CMS profile
123550
Location
AMHERST, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$6,279.38

216 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,779.38 215
Honoraria $1,500.00 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LASZLO L MECHTLER

NPI 1710978598 · CMS profile ID 123550

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

AMHERST, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710978598?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LASZLO L MECHTLER, NPI 1710978598, CMS profile ID 123550. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710978598?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LASZLO L MECHTLER, NPI 1710978598, CMS profile ID 123550. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710978598?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LASZLO L MECHTLER, NPI 1710978598, CMS profile ID 123550, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1710978598?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

216 matching records · $6,279.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 216 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 216.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Tonix Medicines, Inc. $2.9910/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468734 CMS
Tonix Medicines, Inc. $4.0610/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468736 CMS
UCB, Inc. $23.1110/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143044269 CMS
PFIZER INC. $19.1610/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131964279 CMS
Currax Pharmaceuticals LLC $7.3310/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089512574 CMS
PFIZER INC. $14.4209/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131933690 CMS
ABBVIE INC. $19.5309/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012889 CMS
Genentech USA, Inc. $21.4309/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133051239 CMS
SCILEX PHARMACEUTICALS INC. $11.1709/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136271705 CMS
Tonix Medicines, Inc. $7.6709/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468732 CMS
ABBVIE INC. $5.7509/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012887 CMS
UCB, Inc. $22.8909/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143044267 CMS
Impel Pharmaceuticals LLC $17.1809/12/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1156154509 CMS
Tonix Medicines, Inc. $6.2009/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468730 CMS
Currax Pharmaceuticals LLC $9.2209/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089512566 CMS
Lilly USA, LLC $17.5009/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135142645 CMS
Tonix Medicines, Inc. $17.7609/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468728 CMS
ABBVIE INC. $6.6709/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012885 CMS
Teva Pharmaceuticals USA, Inc. $15.0809/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151477314 CMS
Tonix Medicines, Inc. $14.3009/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468726 CMS
Tonix Medicines, Inc. $13.4708/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468724 CMS
ABBVIE INC. $18.5908/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012883 CMS
Currax Pharmaceuticals LLC $12.8208/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089512570 CMS
Impel Pharmaceuticals LLC $16.2008/27/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1156154507 CMS
ABBVIE INC. $31.9608/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012881 CMS
Eisai Inc. $27.2408/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110759640 CMS
Currax Pharmaceuticals LLC $7.0408/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089512568 CMS
Teva Pharmaceuticals USA, Inc. $16.6308/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151477286 CMS
Tonix Medicines, Inc. $13.1008/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468722 CMS
PFIZER INC. $14.1308/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131743144 CMS
IBSA Pharma Inc. $16.4508/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142971928 CMS
PFIZER INC. $24.8008/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131775083 CMS
ABBVIE INC. $28.4208/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012879 CMS
Lilly USA, LLC $16.4608/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135123739 CMS
Tonix Medicines, Inc. $5.8908/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468720 CMS
Lilly USA, LLC $24.0508/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135123737 CMS
Tonix Medicines, Inc. $14.6508/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468718 CMS
ABBVIE INC. $6.1208/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012877 CMS
Tonix Medicines, Inc. $11.1908/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468716 CMS
Currax Pharmaceuticals LLC $7.2008/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089512564 CMS
Lundbeck LLC $13.4208/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145945334 CMS
ABBVIE INC. $6.2408/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012875 CMS
SCILEX PHARMACEUTICALS INC. $9.3508/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136261115 CMS
PFIZER INC. $128.8107/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131779458 CMS
PFIZER INC. $17.4207/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131787218 CMS
Eisai Inc. $23.6407/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110759638 CMS
Tonix Medicines, Inc. $7.8807/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142468714 CMS
ABBVIE INC. $33.3107/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105012873 CMS
SCILEX PHARMACEUTICALS INC. $5.6607/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136260010 CMS
SCILEX PHARMACEUTICALS INC. $15.7107/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136259537 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $49,211.86 172
PY2020 $96,066.85 189
PY2021 $92,720.30 262
PY2022 $39,346.23 212
PY2023 $11,199.05 167
PY2024 $6,279.38 216
PY2025 $52,454.01 228

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $225.97 2
PY2025 Principal investigator $1,299,698.74 35
PY2024 Recipient $8,529.78 4
PY2024 Principal investigator $446,669.83 33
PY2023 Recipient $9,654.80 6
PY2023 Principal investigator $179,684.31 36
PY2022 Principal investigator $180,710.11 39
PY2021 Principal investigator $329,190.05 33
PY2020 Principal investigator $649,986.64 76
PY2019 Recipient $263.00 1
PY2019 Principal investigator $515,462.44 64

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
DENT NEUROLOGIC INSTITUTE
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202534665
Principal investigator 1 ABBVIE INC. $2,163.00 12/31/2025 Non-covered Recipient Entity
DENT NEUROLOGIC INSTITUTE
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 1202534667
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 12/10/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc.
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647276
Principal investigator 1 Merz Pharmaceuticals, LLC $10,000.00 12/10/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc.
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647278
Principal investigator 1 Merz Pharmaceuticals, LLC $10,000.00 12/10/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc.
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647280
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 12/10/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc.
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647282
Principal investigator 1 ABBVIE INC. $1,188.60 12/04/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202526886
Principal investigator 1 ABBVIE INC. $6,577.20 11/05/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202521933
Principal investigator 1 ABBVIE INC. $6,577.20 10/09/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202514383
Principal investigator 1 PFIZER INC. $4,621.90 08/06/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center INC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228754449
Principal investigator 1 ABBVIE INC. $4,338.60 07/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202494373
Principal investigator 1 ABBVIE INC. $1,000.00 07/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202494375
Principal investigator 1 Hyperfine Operations, Inc. $110,322.50 07/02/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center, Inc
HYP-SWOOP-001 No dispute reported 06/30/2026 1225368409
Principal investigator 1 Eli Lilly and Company $5.33 06/16/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187880765
Principal investigator 1 ABBVIE INC. $1,188.60 06/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202488437
Principal investigator 1 Eli Lilly and Company $586,688.05 05/27/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY No dispute reported 06/30/2026 1187881110
Principal investigator 1 ABBVIE INC. $5,527.20 05/07/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483555
Principal investigator 1 Eli Lilly and Company $152.75 05/07/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE 3B, RANDOMIZED, DOUBLE-BLINDED, PLACEBO- CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY (TRIUMPH-6) No dispute reported 06/30/2026 1187882346
Principal investigator 1 ABBVIE INC. $490.05 05/06/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202481945
Principal investigator 1 ABBVIE INC. $3,952.20 04/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202474157
Principal investigator 1 Hyperfine Operations, Inc. $6,525.09 03/26/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center, Inc
NEURO PMR Neurological Evaluation in the Office with Portable MRI No dispute reported 06/30/2026 1244758983
Recipient Eli Lilly and Company $5.97 03/12/2025 Covered Recipient Physician A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187876929
Principal investigator 1 Eli Lilly and Company $782.49 03/10/2025 Non-covered Recipient Entity
UNIVERSITY AT BUFFALO
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187893016
Principal investigator 1 ABBVIE INC. $11,965.80 03/07/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202459728
Recipient Eli Lilly and Company $220.00 03/05/2025 Covered Recipient Physician A PHASE 3B, RANDOMIZED, DOUBLE-BLINDED, PLACEBO- CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY (TRIUMPH-6) No dispute reported 06/30/2026 1187873489
Principal investigator 1 Eli Lilly and Company $7,750.00 02/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187881696
Principal investigator 1 Eli Lilly and Company $1,109.18 02/16/2025 Non-covered Recipient Entity
UNIVERSITY AT BUFFALO
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187890740
Principal investigator 1 ABBVIE INC. $17,378.20 02/06/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202447980
Principal investigator 1 Eli Lilly and Company $7,689.61 01/31/2025 Non-covered Recipient Entity
UNIVERSITY AT BUFFALO
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187892464
Principal investigator 1 Eli Lilly and Company $2,199.30 01/23/2025 Non-covered Recipient Entity
UNIVERSITY AT BUFFALO
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187893232
Principal investigator 1 Eli Lilly and Company $41,446.00 01/21/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187879729
Principal investigator 1 Eli Lilly and Company $28,600.18 01/21/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY No dispute reported 06/30/2026 1187881694
Principal investigator 1 Eli Lilly and Company $5,995.47 01/09/2025 Non-covered Recipient Entity
UNIVERSITY AT BUFFALO
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187891656
Principal investigator 1 Eli Lilly and Company $5,975.44 01/09/2025 Non-covered Recipient Entity
UNIVERSITY AT BUFFALO
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187892060
Principal investigator 1 Eli Lilly and Company $372,925.00 01/07/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187880459
Principal investigator 1 Eli Lilly and Company $27,169.00 01/07/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187880763
Principal investigator 1 ABBVIE INC. $1,794.80 01/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202436178

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $128,455.26 1
PY2025 Value of interest $307,407.37 1
PY2024 Amount invested $64,639.69 1
PY2024 Value of interest $178,952.11 1
PY2023 Amount invested $36,888.64 1
PY2023 Value of interest $114,312.42 1
PY2022 Amount invested $36,968.45 1
PY2022 Value of interest $77,423.78 1
PY2021 Amount invested $16,550.50 1
PY2021 Value of interest $40,455.33 1
PY2020 Amount invested $15,270.32 1
PY2020 Value of interest $23,904.84 1
PY2019 Amount invested $8,290.25 1
PY2019 Value of interest $8,634.52 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $128,455.26 $307,407.37 Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. Payments are made to a group practice, not directly to the physician. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buy down per physician clinic as a result of the practice ownership in the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1246636640
PY2024 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $64,639.69 $178,952.11 1.) Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. 2.) Payments are made to a group practice rather than to a specific physician. The group practice owns 50% of the GPO. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buydown per physician clinic as a result of the practice ownership in the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1087844295
PY2023 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $36,888.64 $114,312.42 1.) Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. 2.) Payments are made to a group practice rather than to a specific physician. The group practice owns 50% of the GPO. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buydown per physician clinic as a result of the practice ownership in the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1056921979
PY2022 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $36,968.45 $77,423.78 The organization the physician practices at owns 50% of the GPO, therefore 50% of the profit goes to the medical practice. Physician Covered Recipient No dispute reported 06/30/2026 961728707
PY2021 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $16,550.50 $40,455.33 The organization the physician practices at owns 50% of the GPO, therefore 50% of the profit goes to the medical practice. Physician Covered Recipient No dispute reported 06/30/2026 851039295
PY2020 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $15,270.32 $23,904.84 Physician is employed at outpatient neurology practice that owns a percentage of the GPO Physician Covered Recipient No dispute reported 06/30/2026 753246339
PY2019 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $8,290.25 $8,634.52 Physician is employed at outpatient neurology practice that owns a percentage of the GPO Physician Covered Recipient No dispute reported 06/30/2026 708351861